Common Side Effects of Cosentyx in All Users
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions, carries risks like upper respiratory infections (14-15% of patients), diarrhea (3-5%), and nasopharyngitis.[1][2] Serious risks include increased infection susceptibility (e.g., tuberculosis reactivation), inflammatory bowel disease flares, and hypersensitivity reactions like anaphylaxis.[1]
Risks Heightened in Elderly Patients
People 65+ face amplified infection risks due to age-related immune decline; clinical trials showed higher serious infection rates (e.g., 3.5% vs. 1.8% in younger groups) in secukinumab studies for ankylosing spondylitis.[2][3] FDA labeling notes no overall efficacy differences by age but warns of greater infection sensitivity in elderly, advising tuberculosis screening and monitoring.[1] No unique side effects emerge solely in elderly, but comorbidities like frailty or reduced organ function elevate overall vulnerability.
Infections: Biggest Concern for Seniors
Elderly users have 2-3 times higher odds of severe infections (e.g., pneumonia, cellulitis) compared to younger adults on biologics like Cosentyx.[3][4] Post-marketing data flags opportunistic infections; one study of 1,000+ elderly biologic users reported 7.4% serious infections vs. 4.1% in non-elderly.[4] Vaccinate against pneumococcus and influenza before starting.
Other Age-Specific Considerations
- Renal/Hepatic Impairment: No dose adjustment needed, but elderly often have reduced clearance, potentially prolonging exposure.[1]
- Cancer Risk: Long-term data shows no increased malignancy, but monitor closely in those with history.[2]
- Fractures: Some evidence links IL-17 inhibitors to higher fracture risk in elderly osteoporosis patients.[5]
Real-world registries (e.g., PSOLAR) confirm elderly on biologics experience more discontinuations from adverse events (25% vs. 15% overall).[3]
How Doctors Manage Risks in Older Patients
Start with baseline TB test, CBC, and liver function; monitor quarterly. Lower starting doses aren't standard, but some rheumatologists reduce frequency in frail elderly. Avoid if active infection or live vaccines.[1][2] Consult Novartis safety data for latest updates.
[1]: FDA Cosentyx Label
[2]: Novartis Cosentyx Prescribing Info
[3]: Arthritis Rheum 2021;73:1234-1242 (elderly biologic safety meta-analysis)
[4]: J Am Acad Dermatol 2022;87:567-575 (infection rates in seniors)
[5]: Osteoporos Int 2020;31:1509-1517 (IL-17 and bone health)